Nemocnice Slany
- Address
- lock Available on a paid plan
Nemocnice Slany - Advanced Cardiovascular, Gastroenterology, and Metabolic Research Center
Nemocnice Slany is a comprehensive medical research facility with extensive expertise in investigating novel therapeutic interventions across multiple disease areas. The center demonstrates particular strength in cardiovascular disease research, including heart failure, atrial fibrillation, and atherosclerotic cardiovascular disease, as well as significant involvement in inflammatory bowel disease studies.
- Cardiovascular research including heart failure with preserved/reduced ejection fraction, atrial fibrillation anticoagulation trials, and novel therapies for acute and chronic heart failure
- Inflammatory bowel disease studies focusing on ulcerative colitis and Crohn's disease with advanced biologics and targeted therapies
- Chronic kidney disease and hypertension management including novel aldosterone synthase inhibitors and SGLT2 inhibitor combinations
- Metabolic disorders including severe hypertriglyceridemia and lipid management with innovative RNA therapeutics
The facility's research portfolio includes participation in large-scale Phase III trials evaluating cutting-edge treatments such as anticoagulant therapies for atrial fibrillation, SGLT2 inhibitors combined with novel agents for cardiorenal protection, and biosimilar studies. The center also contributes to vaccine development research for invasive bacterial infections and demonstrates capability in conducting complex adaptive dose-ranging studies across multiple therapeutic areas, positioning it as a versatile clinical research center capable of managing diverse patient populations and complex study protocols.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 5 therapeutic areas and 15 of 49 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 49 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 11 by active trials.
lock +10 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
lock +9 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 634 other sites in Czechia
Therapeutic Area Benchmark — Czechia
Select a therapeutic area to compare against other sites in Czechia.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Czechia
Market Share
Country: Czechia
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Nemocnice Slany
lock Showing 1 of 43 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Tulisokibart in Participants with Moderately to Severely Active Ulcerative Colitis | Merck Sharp & Dohme LLC | Phase III | Not Recruiting | Aug 2024 | — |
IMP list
lock Showing 1 of 49 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Duvakitug | 6 | Unknown | 2023-03-17 | 2026-07-22 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.